Methotrexate plus immunotherapy combo for untreated PCNSL
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed type of lymphoma (DLBCL) that is only in your brain, spinal cord, or eyes.
- You have not had any previous treatment for lymphoma (except steroids).
- You have a measurable tumor on MRI or lymphoma cells in your spinal fluid.
- You have adequate blood counts and liver/kidney function.
- You are not pregnant, and if you could become pregnant, you agree to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial compares two treatment combinations for newly diagnosed primary CNS lymphoma (PCNSL), a rare type of brain lymphoma. It tests whether adding a drug called PD-1 (a type of immunotherapy that helps your immune system fight cancer) to the standard chemotherapy (R-MA) improves outcomes compared to R-MA alone. Participating gives access to a novel combination that may be more effective, though it involves extra monitoring and possible immune-related side effects.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a combination of three drugs (pomalidomide, rituximab, and methotrexate) for people who have just been diagnosed with a type of lymphoma that started in the brain or spinal cord. The goal is to see if this drug cocktail is safe and effective as a first treatment.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.